iota Biosciences

iota Biosciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

iota Biosciences is a private, clinical-stage bioelectronics company developing a novel platform of ultrasound-powered, ultra-miniature implantable devices. Its core technology, originating from UC Berkeley research, enables wireless, battery-free neural interfaces for therapeutic neuromodulation and sensing. The company is advancing programs in neurological and urological therapies, backed by the strategic partnership and resources of its parent company, Astellas Pharma.

NeurologyUrology

Technology Platform

Ultrasound-powered, millimeter-scale, wireless, battery-free implantable bioelectronic devices for neural sensing and stimulation.

Funding History

2
Total raised:$50M
Series A$35M
Seed$15M

Opportunities

The platform's miniaturization and wireless design could expand neuromodulation to new patient populations and anatomical targets, addressing large unmet needs in chronic neurological and urological diseases.
Long-term, the versatile technology enables a pipeline across cardiology, immunology, and endocrinology, representing a multi-billion-dollar market.

Risk Factors

Key risks include unproven long-term safety and efficacy of the novel implant platform in humans, complex regulatory pathways for a first-in-class device, and future challenges in commercial adoption against established therapies.
Technical hurdles in consistent device performance and bio-compatibility also remain.

Competitive Landscape

iota competes in the neuromodulation and bioelectronic medicine space against large medtech players (e.g., Medtronic, Boston Scientific, Abbott) with traditional implanted systems, and a growing number of startups developing miniaturized/wireless solutions (e.g., SetPoint Medical, NeuroOne). Its ultrasound-powered, battery-free approach is a key differentiator.